Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Spinak

Ophthalmology Silverdale, WA Medical Doctor

NPI 1942232913 CMS profile 360946

9800 Levin Rd Nw, Ste 203, Silverdale, WA 98383

Open in the dashboard

General payments

$779

24 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$350,202 paid to institutions, not to them · program years 2019–2024

Through program year 2025, David Spinak of Silverdale, WA is reported in the CMS Open Payments database as having received $779 across 24 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $350,202 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 39th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60 3
2024 General $242 2
2023 General $120 6
2022 General $195 10
2019 General $163 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Spinak
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to David Spinak were reported at $60. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year David Spinak Ophthalmology median Middle half National median
2019 $163 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $0 $205 $76–$534 $132
2022 $195 $266 $100–$678 $149
2023 $120 $308 $117–$745 $160
2024 $242 $340 $127–$846 $164
2025 $60 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $150 1 payment
  2. Allergan Inc. $138 2 payments
  3. Genentech USA, Inc. $132 7 payments
  4. Sight Sciences, Inc. $92 1 payment
  5. Coherus Biosciences Inc. $63 3 payments
  6. Alimera Sciences, Inc. $54 3 payments
  7. EyePoint Pharmaceuticals US, Inc. $31 2 payments
  8. Carl Zeiss Meditec USA, Inc. $31 1 payment
  9. Topcon Medical Systems, Inc. $30 2 payments
  10. ANI Pharmaceuticals, Inc. $29 1 payment
  11. Other $28 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $779 24 payments
Products named General payments · program years 2019–2025
  1. AcrySof IQ PanOptix UV IOL $150 1 payment
  2. AcrySof IQ VIVITY $150 1 payment
  3. OZURDEX $138 2 payments
  4. OMNI SURGICAL SYSTEM $92 1 payment
  5. VABYSMO $90 5 payments
  6. Cimerli $63 3 payments
  7. ILUVIEN Ophthalmology $54 3 payments
  8. YUTIQ $31 2 payments
  9. CLARUS $31 1 payment
  10. ILUVIEN treatment of diabetic macular edema in patients who have been previously treated with corticosteroid $29 1 payment
  11. Other $38 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

108

Median for Ophthalmology: 891

Drug cost

$2,807

Median for Ophthalmology: $68,233

Branded share of claims

21.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 43 $2,061
Diclofenac Sodium Generic 42 $483
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 23 $263

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$4,723,955

Of which drugs: $4,065,761

Medicare patients

1,141

Average age 78

Services billed

54,885

671 women, 470 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 42%
Diabetes 28%
Ischemic heart disease 25%
Chronic kidney disease 22%
Atrial fibrillation 20%
Heart failure 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept hd, 1 mg J0177 Office 168 4,552 $1,199,495
Injection, pegcetacoplan, intravitreal, 1 mg J2781 Office 87 8,070 $943,801
Injection, faricimab-svoa, 0.1 mg J2777 Office 85 30,060 $818,293
Injection, aflibercept, 1 mg J0178 Office 186 1,202 $766,904
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg Q5128 Office 84 1,096 $215,431
Injection, dexamethasone, intravitreal implant, 0.1 mg J7312 Office 15 259 $41,611
Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg Q5124 Office 11 245 $32,722

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record